GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91.
Published April 15, 2026 · Recall initiated: March 24, 2026
Summary
FDA records drug Class II recall D-0448-2026, published April 15, 2026 and initiated March 24, 2026. Recalling firm: GE Healthcare Ireland Limited; Status: Ongoing; Reported quantity: 306,810 vials; Lot: Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. January 1, 2029 Lot# 17426440; Exp. January 4, 2029 Lot# 17431310; Exp. January 11, 2029. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of particulate matter
What to do
Voluntary: Firm initiated
Get an email if OMNIPAQUE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OMNIPAQUE
- Manufacturer
- GE Healthcare Ireland Limited
- Distributor
- U.S. Nationwide.
- Lot
- Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. January 1, 2029 Lot# 17426440; Exp. January 4, 2029 Lot# 17431310; Exp. January 11, 2029
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- Ireland
Related recalls
- FDAGE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc.,April 15, 2026
- FDAClonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, RxApril 15, 2026
- FDAIsotretinoin Capsules, USP, 40 mg, 10 count Prescription Pacs, Rx only, Manufactured for: Teva PharmaceuticalsApril 15, 2026
- FDAClonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, RxApril 15, 2026
- FDAIsotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack, Manufactured for: Teva PharmaceuticalsApril 15, 2026
- FDAOmnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, RxDecember 26, 2018
Questions about this recall
Was GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91. recalled?
Yes. FDA published recall D-0448-2026 on April 15, 2026. Reported hazard: Presence of particulate matter
What should I do if I have this product?
Voluntary: Firm initiated
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OMNIPAQUE.